Hotline update of clinical trials and registries presented at the German Cardiac Society Meeting 2009

Maier, Lars S.; Schirmer, Stephan H.; Walenta, Katrin; Jacobshagen, Claudius; Böhm, Michael

doi:10.1007/s00392-009-0027-z

Cited by 6 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the current guidelines for the treatment of myocardial infarctions, rapid ECG assessment is mandatory in patients with chest pain and acute coronary syndromes contributing to a reduction in door- and contact-to-balloon times to primary angioplasty [ 2 – 4 , 15 – 17 ]. Usually, conventional ECG assessment including undressing takes about 2–3 min.…”

Section: Discussionmentioning

confidence: 99%

First clinical evaluation of a novel capacitive ECG system in patients with acute myocardial infarction

et al. 2011

View full text Add to dashboard Cite

ObjectiveThe ECG plays a central role in the rapid diagnosis of acute myocardial infarctions (MI). In haemodynamically instable patients, adhesion of electrodes sometimes is difficult and assessing ECGs through layers of clothes has not been done so far. A novel capacitive measurement of ECG signals is possible without skin contact. Whether this technical innovation can be used in patients with MI is unclear.MethodsWe evaluated a capacitive ECG system (cECG) in patients with anterior and inferior ST elevation MI (STEMI) as compared to patients without ST elevations in anterior and inferior leads. The cECG was assessed using a sensor array consisting of 15 electrodes of which the classical leads I, II, III, aVL, aVF and V1–V3 were calculated from. 66 patients were included in the study. In addition to the conventional ECG (kECG) the novel cECG was registered before reperfusion therapy was started.ResultsIn a first round, 19 patients presented with anterior MI, 23 with inferior MI, and 7 either with left bundle branch block or lateral MI. Regarding anterior MI, a significant correlation (P < 0.05) was found between ST elevations in leads I, aVL, V2 and V3 comparing cECG and kECG. In inferior MI, there was only a significant correlation (P < 0.05) in lead III between cECG and kECG, but not in II and aVF. Therefore, 17 additional patients were included in the study by placing an additional electrode further away from the sensor array on the chest. ST elevations now correlated in all inferior leads II, III and aVF (P < 0.05) as measured in 9 patients with inferior MI. In addition, in 8 patients an inferior MI was correctly ruled out.ConclusionIt is possible to identify STEMIs by cECG. This innovative technique could play an important role in the pre-hospital period as well as in the hospital.

show abstract

Section: Discussionmentioning

confidence: 99%

First clinical evaluation of a novel capacitive ECG system in patients with acute myocardial infarction

et al. 2011

View full text Add to dashboard Cite

show abstract

“…‘KardioPro’ is a cardiovascular prevention programme supplied by SBK [4] . It covers complex pathways of diagnosis and treatment which differ according to the subjects' risk group.…”

Section: Methodsmentioning

confidence: 99%

“…The German health insurance fund SBK (SBK = ‘Siemens-Betriebskrankenkasse’), a large statutory sickness fund with more than one million insured people, offered their insurants the complex prevention programme ‘KardioPro’ [4] . This programme provides risk-dependent decision algorithms regarding the diagnosis and treatment of coronary heart disease (CHD).…”

Section: Introductionmentioning

confidence: 99%

The Effectiveness of the Cardiovascular Disease Prevention Programme ‘KardioPro’ Initiated by a German Sickness Fund: A Time-to-Event Analysis of Routine Data

et al. 2014

View full text Add to dashboard Cite

BackgroundCardiovascular disease is the leading cause of morbidity and mortality in the developed world. To reduce this burden of disease, a German sickness fund (‘Siemens-Betriebskrankenkasse’, SBK) initiated the prevention programme ‘KardioPro’ including primary (risk factor reduction) and secondary (screening) prevention and guideline-based treatment. The aim of this study was to assess the effectiveness of ‘KardioPro’ as it is implemented in the real world.MethodsThe study is based on sickness fund routine data. The control group was selected from non-participants via propensity score matching. Study analysis was based on time-to-event analysis via Cox proportional hazards regression with the endpoint ‘all-cause mortality, acute myocardial infarction (MI) and ischemic stroke (1)’, ‘all-cause mortality (2)’ and ‘non-fatal acute MI and ischemic stroke (3)’.ResultsA total of 26,202 insurants were included, 13,101 participants and 13,101 control subjects. ‘KardioPro’ enrolment was associated with risk reductions of 23.5% (95% confidence interval (CI) 13.0–32.7%) (1), 41.7% (95% CI 30.2–51.2%) (2) and 3.5% (hazard ratio 0.965, 95% CI 0.811–1.148) (3). This corresponds to an absolute risk reduction of 0.29% (1), 0.31% (2) and 0.03% (3) per year.ConclusionThe prevention programme initiated by a German statutory sickness fund appears to be effective with regard to all-cause mortality. The non-significant reduction in non-fatal events might result from a shift from fatal to non-fatal events.

show abstract

“…dissections [62]. However, the reported bail-out stenting requirements vary from 3% to 20% [140,170,171]. DEB angioplasty should be done differently from standard PCI.…”

Section: High Bail-out Stentingmentioning

confidence: 99%

Drug-eluting balloon: design, technology and clinical aspects

2018

View full text Add to dashboard Cite

A drug-eluting balloon is a non-stent technology in which the effective homogenous delivery of anti-proliferative drugs is processed by the vessel wall through an inflated balloon. This is done to restore luminal vascularity in order to treat atherosclerosis, in-stent restenosis and reduce the risk of late thrombosis without implanting a permanent foreign object. The balloon technology relies on the concept of targeted drug delivery, which helps in the rapid healing of the vessel wall and prevents the proliferation of smooth muscle cells. Several drug eluting devices in the form of coated balloons are currently in clinical use, namely DIOR, PACCOCATH, SeQuentPlease and IN.PACT™. The device varies in terms of the material used for making the balloon, the coating techniques, the choice of coated drug and the release pattern of the drug at the site. This review gives an insight into the evolution, rationale and comparison of the marketed drug-eluting balloons. Here, different coating techniques have been analysed for the application and critical analysis of available DEB technologies, and a technical comparison has been done.

show abstract

Hotline update of clinical trials and registries presented at the German Cardiac Society Meeting 2009

Cited by 6 publications

References 11 publications

First clinical evaluation of a novel capacitive ECG system in patients with acute myocardial infarction

First clinical evaluation of a novel capacitive ECG system in patients with acute myocardial infarction

The Effectiveness of the Cardiovascular Disease Prevention Programme ‘KardioPro’ Initiated by a German Sickness Fund: A Time-to-Event Analysis of Routine Data

Drug-eluting balloon: design, technology and clinical aspects

Contact Info

Product

Resources

About